Back to results
US 6,271,202 B1Granted
Reduction of impairment of respiratory tract mucosal immunity
AssigneeThe University of Tennessee Research Corporation
InventorKenneth A. Kudsk
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe University of Tennessee Research Corporation
InventorKenneth A. Kudsk
Estimating the term…
The present invention describes methods for reducing the impairment respiratory tract mucosal immunity associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. Also described are methods for reducing the rate of infection of the respiratory tract by pathogenic microorganisms associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. In addition, a method of reducing the atrophy or dysfunction of the GALT comprising administering a therapeutically effective amount of a neuropeptide is described. The specification further describes compositions for reducing or preventing the impairment of intestinal or respiratory tract mucosal immunity comprising a neuropeptide and a pharmaceutically acceptable carrier.
A method of reducing the rate of infection of the respiratory tract by a pathogenic microorganism in an animal associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide selected from the group consisting of bombesin, gastrin-releasing polypeptide, a neuropeptide having an amino acid C terminus corresponding to Trp-Ala-Val-Gly-His-Leu-Met-NH2, [SEQ ID NO:1], and a mixture thereof.
A method of reducing the rate of infection of the respiratory tract by a pathogenic microorganism in an animal associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a compound which stimulates the release of a neuropeptide selected from the group consisting of bombesin, gastrin-releasing polypeptide, a neuropeptide having an amino acid C terminus corresponding to Trp-Ala-Val-Gly-His-Leu-Met-NH2 [SEQ ID NO:1], and a mixture thereof.
A method of reducing the rate of infection of the respiratory tract by pathogenic microorganisms in an animal associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a compound which is released in response to a neuropeptide selected from the group consisting of bombesin, gastrin-releasing polypeptide, a neuropeptide having an amino acid C terminus corresponding to Trp-Ala-Val-Gly-His-Leu-Met-NH2, and a mixture thereof.
A method of reducing the rate of infection of the respiratory tract by a pathogenic microorganism in an animal associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide consisting essentially of Trp-Ala-Val-Gly-His-Leu-Met-NH2 [SEQ ID NO:1].
A composition useful in reducing the rate of infection of the respiratory tract by a pathogenic microorganism in an animal associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising a therapeutically effective amount of a neuropeptide consisting essentially of Trp-Ala-Val-Gly-His-Leu-Met-NH2, [SEQ ID NO:1] and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.